Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Neem bark from Azadirachta indica contains triterpenoids like nimbidin and nimbin that demonstrate antimicrobial activity by disrupting bacterial cell walls and inhibiting COX-2 inflammatory pathways. Clinical evidence remains limited, with most therapeutic support derived from in vitro studies and traditional Ayurvedic applications.
Reported Benefits (Provisional)
Origin & History
Neem Bark, from the *Azadirachta indica* tree, is native to the Indian subcontinent, including India, Bangladesh, Myanmar, and Sri Lanka. Flourishing in dry tropical and subtropical climates, this revered botanical is a cornerstone in traditional healing systems for its potent detoxifying and antimicrobial properties.
Research Narrative (Provisional)
Research, including in vitro and animal studies, supports Neem Bark's antimicrobial, anti-inflammatory, and hepatoprotective properties. Further clinical trials are needed to fully establish its efficacy in human health, particularly for its traditional uses in detoxification and metabolic balance.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Minerals: Calcium, Magnesium, Zinc - Phytochemicals: Azadirachtin, Nimbin, Nimbidin, Flavonoids, Polyphenols, Tannins, Triterpenoids, Polysaccharides
Reported Mechanism (Provisional)
Nimbidin and nimbin disrupt microbial cell wall synthesis and membrane integrity while suppressing COX-2 enzyme activity to reduce inflammatory prostaglandin production. Phenolic compounds and flavonoids provide antioxidant protection through free radical scavenging via hydroxyl groups. These bioactive compounds also modulate immune responses by downregulating NF-κB inflammatory pathways and inhibiting nitric oxide release in activated macrophages.
Clinical Narrative (Provisional)
Clinical evidence for neem bark remains extremely limited, with only one small trial in HIV patients showing increased CD4+ and CD8+ cell counts following neem bark powder treatment, though specific dosages and sample sizes were not reported. Most therapeutic evidence derives from in vitro studies demonstrating antimicrobial activity against E. coli, S. aureus, P. aeruginosa, and C. albicans. Preclinical research shows NF-κB inhibition with IC50 values of 220-250 μg/ml in cell cultures, but large-scale randomized controlled trials in humans are lacking. The clinical application is significantly limited by toxicity concerns, poor bioavailability, and standardization issues.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.